Immunicum to participate upcoming

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company specializing in therapies for tumor recurrence and hard-to-treat established tumors, today announced participation in the following conferences:

Red eye growth day 2022

June 2, 2022

Immunicum CEO Erik Manting will participate in an on-site Q&A session on June 2 at 08:55 CET. Further details, including the on-demand corporate presentation, are available via:
https://redeye.ifairs.com/#/booth?id=687

BioStock Life Sciences Spring Summit

June 8-9, 2022

Immunicum CEO Erik Manting will present on June 9 at 10:20 a.m. CET.

BioStock Life Science Spring Summit, June 8-9

European Hematology Association (EHA) Congress 2022

June 9-17, 2022

https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/

Organic International Convention

June 13-16, 2022

https://www.bio.org/events/bio-international-convention

FOR MORE INFORMATION PLEASE CONTACT:

Erik Manting

Chief executive officer

Email: [email protected]

INVESTOR RELATIONS

Julie Seidel

Serious investor relations

Telephone: +1 212-362-1200

Email: [email protected]

MEDIA RELATIONS

Mario Brkulj

Valencia Communications

Telephone: +49 160 9352 9951

Email: [email protected]

ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company specializing in therapies for tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We leverage our unrivaled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel off-the-shelf cell therapies for solid and blood-borne tumors. Based in Sweden and the Netherlands, Immunicum is listed on Nasdaq Stockholm. www.immunicum.com

  • 220601_Immunicum_Conferences_June_ENG

About Stephen Arrington

Check Also

Nikki Haley speaks at a conference as January 6 hearings continue

Former UN ambassador Nikki Haley helped kick off a conference of prominent conservatives in Nashville …